<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Dekker EN</submitter><funding>NCI NIH HHS</funding><funding>The Dutch Cancer Society</funding><funding>ZonMw</funding><pagination>znae244</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11472162</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>111(10)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Patients with localized (that is non-metastatic) pancreatic ductal adenocarcinoma with an inadequate response or toxicity to first-line chemotherapy may benefit from chemotherapy switch. The aim was to explore the available data on the use and effect of chemotherapy switch, as reported in the literature.&lt;h4>Methods&lt;/h4>A systematic search was conducted in Embase, MEDLINE (Ovid), the Web of Science, Cochrane, and Google Scholar on 1 December 2023. The main outcomes were the proportion of patients who underwent chemotherapy switch and the carbohydrate antigen 19-9 response and resection, R0 resection, and ypN0 resection rates after chemotherapy switch. Data were pooled using a random-effects model.&lt;h4>Results&lt;/h4>A total of five retrospective studies, representing 863 pati</pubmed_abstract><journal>The British journal of surgery</journal><pubmed_title>Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis.</pubmed_title><pmcid>PMC11472162</pmcid><funding_grant_id>13417</funding_grant_id><funding_grant_id>P30 CA008748</funding_grant_id><funding_grant_id>10140022010009</funding_grant_id><pubmed_authors>Meddouch A</pubmed_authors><pubmed_authors>Dekker EN</pubmed_authors><pubmed_authors>O'Kane GM</pubmed_authors><pubmed_authors>Wilmink JW</pubmed_authors><pubmed_authors>Qadan M</pubmed_authors><pubmed_authors>Groot Koerkamp B</pubmed_authors><pubmed_authors>O'Reilly EM</pubmed_authors><pubmed_authors>Besselink MGH</pubmed_authors><pubmed_authors>Narayan RR</pubmed_authors><pubmed_authors>Ahmami MA</pubmed_authors><pubmed_authors>de Wilde RF</pubmed_authors><pubmed_authors>Verkolf EMM</pubmed_authors><pubmed_authors>Gehrels AM</pubmed_authors><pubmed_authors>van Eijck CHJ</pubmed_authors><pubmed_authors>Homs MYV</pubmed_authors><pubmed_authors>Mostert B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis.</name><description>&lt;h4>Background&lt;/h4>Patients with localized (that is non-metastatic) pancreatic ductal adenocarcinoma with an inadequate response or toxicity to first-line chemotherapy may benefit from chemotherapy switch. The aim was to explore the available data on the use and effect of chemotherapy switch, as reported in the literature.&lt;h4>Methods&lt;/h4>A systematic search was conducted in Embase, MEDLINE (Ovid), the Web of Science, Cochrane, and Google Scholar on 1 December 2023. The main outcomes were the proportion of patients who underwent chemotherapy switch and the carbohydrate antigen 19-9 response and resection, R0 resection, and ypN0 resection rates after chemotherapy switch. Data were pooled using a random-effects model.&lt;h4>Results&lt;/h4>A total of five retrospective studies, representing 863 pati</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Oct</publication><modification>2026-07-15T17:41:19.323Z</modification><creation>2025-04-04T00:29:14.121Z</creation></dates><accession>S-EPMC11472162</accession><cross_references><pubmed>39400008</pubmed><doi>10.1093/bjs/znae244</doi></cross_references></HashMap>